🔗 Share this article

As the United States proceeds with sweeping revisions to its vaccine recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by questioning Covid vaccines in the global health crisis and has zeroed in on alleged deaths after Covid immunization in her recent time at the US Food and Drug Administration (FDA).

Proposed Shifts to Childhood Immunization Program

Agency leaders were set to unveil major revisions to the childhood immunization program in December, synchronizing the US with the Danish national calendar, it is understood – a major change that would place the US out of step with much of the international standard with little proof for benefit. This reveal has been postponed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this calendar year.

A New Direction at the Agency

The acting appointment could signify a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a renewed priority upon rolling back long-standing vaccines at the FDA.

Høeg has repeatedly called for discontinuing certain childhood shot schedules in the US so as to align more like Denmark, a nation with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

So far statements, she has kept her attention on immunizations – typically the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Background

Dr. Høeg has no apparent track record in pharmaceutical research, oversight or leadership, which has been typical for previous directors of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have the necessary background” for leading the drug-regulation department, remarked Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a major agency. She lacks background in industry regulation.”

Former heads of CBER would “grasp regulatory frameworks and the science of drug development”, said Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that former directors who ran CBER have had.”

The drug center has an vast range of responsibilities at the FDA, she stated.

“Many people just focuses on the new drug program, but the generic program clears a multitude of generic drugs. There is also a biosimilars program, non-prescription drug unit and other areas, and each of these need to be managed,” she noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership element to the role, which manages more than 5,000 personnel. “It is a enormous leadership role, if you perform it correctly,” the former official added.

Response and Contentious Programs

In response to inquiries about Høeg’s qualifications and whether this selection represents more teamwork among agency officials on immunizations, a spokesperson stated that the “concerns are based on incorrect presumptions”.

“Her resume matches the responsibilities of her position,” the official stated, noting the months Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg takes over the agency head's controversial expedited review system, a contentious one-day drug-approval program that apparently worried her predecessors. “How are these medications being selected for this voucher program? Who makes the decisions?” Howard questioned. “There is a lot of secrecy occurring at the regulatory body right now.”

In general, he remarked, “the agency appears to be shifting towards more relaxed rules of all drugs, aside from shots.”

Public History on Immunizations

With immunizations, Høeg has a more documented, if concerning, past, critics said. She published a research paper using unverified volunteer-provided data to assess the frequency of myocarditis after COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the incoming government encompassed revising guidelines for recently developed shots and ending “unnecessary” immunizations, she remarked post-election on a online show. At the agency, Dr. Høeg has according to sources suggested preventing adolescent males from receiving Covid vaccines.

“She is an all-around dogmatist who commences with her beliefs and works backwards to accommodate the evidence in a extremely deceptive, fraudulent way,” Howard said.

Gaining Influence and a “Revenge Tour”

Høeg joined fellow contrarians, {like|